By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Leerink Swann today began coverage of Fluidigm with an "Outperform" rating and a $17 to $18 valuation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.